Julie Green Sells 18,425 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 18,425 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total value of $15,477.00. Following the completion of the transaction, the insider owned 168,937 shares in the company, valued at $141,907.08. This represents a 9.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Julie Green also recently made the following trade(s):

• On Monday, August 17th, Julie Green sold 22,355 shares of Invivyd stock. The stock was sold at an average price of $0.72, for a total transaction of $16,095.60.

Invivyd Stock Performance

Shares of IVVD stock traded up $0.13 during trading on Tuesday, hitting $0.87. 7,732,095 shares of the company were exchanged, compared to its average volume of 3,061,089. The firm has a market capitalization of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The business’s 50-day simple moving average is $0.77 and its 200 day simple moving average is $1.23. Invivyd, Inc. has a twelve month low of $0.48 and a twelve month high of $3.07.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The company had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. On average, equities analysts forecast that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of IVVD. Eventide Asset Management LLC bought a new position in shares of Invivyd during the 4th quarter valued at $14,349,000. Perceptive Advisors LLC bought a new stake in Invivyd in the fourth quarter worth $53,809,000. BVF Inc. IL bought a new stake in Invivyd in the fourth quarter worth $48,227,000. UBS Group AG increased its position in Invivyd by 683.8% during the fourth quarter. UBS Group AG now owns 1,050,923 shares of the company’s stock worth $2,596,000 after buying an additional 916,842 shares during the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new position in Invivyd during the first quarter worth $25,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on IVVD shares. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. HC Wainwright restated a “buy” rating on shares of Invivyd in a research note on Tuesday. Finally, Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.